Popiela T, Zembala M, Oszacki J, Jedrychowski W
Cancer Immunol Immunother. 1982;13(3):182-4. doi: 10.1007/BF00205385.
Two hundred and seventeen patients with advanced gastric cancer were classified according to the resectability of the tumour into two groups: I, resectable (non-radical surgery), 99 patients, and II, non-resectable carcinoma, 118 patients. Within each group patients were randomly assigned to receive 5-fluorouracil (5-FU) + BCG, 5-FU, or no further treatment (surgery only). BCG was given by scarification. A 2-year follow-up is reported. The group of patients with resectable tumours and receiving chemoimmunotherapy had a statistically significant prolongation of survival compared with the 5-FU and surgery only groups. No differences in survival were observed between these treatment modalities in patients with non-resectable tumour. These observations indicate that chemoimmunotherapy may be of benefit for a selected group of patients with gastric cancer.
217例晚期胃癌患者根据肿瘤的可切除性分为两组：I组，可切除（非根治性手术），99例；II组，不可切除癌，118例。每组患者随机分配接受5-氟尿嘧啶（5-FU）+卡介苗、5-FU或不进行进一步治疗（仅手术）。卡介苗采用划痕法接种。报告了2年的随访情况。与仅接受5-FU和手术的组相比，可切除肿瘤且接受化学免疫疗法的患者组生存期有统计学意义的延长。在不可切除肿瘤的患者中，这些治疗方式之间未观察到生存期差异。这些观察结果表明，化学免疫疗法可能对特定的胃癌患者群体有益。
